# Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays

## TL;DR

This study compares how αβ and γδ T cells respond to Blinatumomab, a cancer drug, in lab tests, finding that γδ T cells could help improve treatment effectiveness.

## Contribution

The study reveals subset-specific responses of αβ and γδ T cells to Blinatumomab and suggests γδ T cells as potential complements in therapy.

## Key findings

- Freshly isolated αβ T cells showed better BLN-mediated cytotoxicity than γδ T cells.
- Zoledronate-expanded γδ T cells achieved cytotoxicity comparable to αβ T cells.
- γδ T cells showed a stable effector-memory profile with low checkpoint expression.

## Abstract

Blinatumomab (BLN) is a bispecific T-cell engager that has revolutionized the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), significantly improving outcomes in both adults and children. By simultaneously binding to CD19 on B cells and CD3 on T cells, BLN triggers target cell-dependent T-cell activation, resulting in the cytolysis of CD19+ BCP-ALL cells. Despite the remarkable clinical advancements achieved with BLN, the immunological mechanisms underlying treatment response or failure remain poorly characterized. γδ T cells are attractive candidates for adoptive T-cell therapy due to potent cytotoxicity, capacity to present antigens, broad lysis of different tumor entities, and low alloreactivity. Because γδ T cells can also be redirected by BLN, we systematically studied BLN-driven effector functions in vitro in conventional αβ and unconventional γδ T cells from healthy donors.

We evaluated cytotoxicity and cytokine/effector release in freshly isolated and in vitro-expanded αβ and γδ T cells from healthy adults against CD19+ BCP-ALL cell lines (NALM-6, HAL-01), and profiled dynamic phenotypic alterations by multiparametric flow cytometry.

CD19+ targets were consistently reduced in the presence of BLN. Freshly isolated αβ, especially CD8+, displayed superior BLN-mediated effector functions as compared to γδ T cells, with donor-dependent variability in γδ killing. Notably, zoledronate-expanded Vγ9Vδ2 γδ T-cell lines achieved cytotoxicity comparable to PHA-expanded αβ cells. However, γδ T-cell-killing benefited from higher BLN concentration when challenged with high tumor load. In these in vitro healthy-donor T-cell cultures, BLN induced CD3 down-modulation in αβ T cells but not in γδ T cells, and αβ cultures released higher soluble Fas ligand, findings consistent with stronger early activation and suggestive of increased susceptibility to activation-associated apoptosis/AICD. Exploratory targeted single-cell transcriptomics (one donor) supported a pronounced activation/exhaustion program in αβ T cells and a comparatively stable effector-memory profile with low checkpoint expression in γδ T cells.

Together, these in vitro data reveal subset-specific BLN responses and support the hypothesis that ex vivo-expanded Vγ9Vδ2 γδ T cells could complement BLN-mediated cytotoxicity, particularly under conditions of higher CD19 density and lower target burden. These findings provide a mechanistic framework for future testing of γδ T-cell/BLN combination strategies in patient-derived models and clinical studies.